APA

Shapiro G. I., Tibes R., Gordon M. S., Wong B. Y., Eder J. P., Borad M. J., Mendelson D. S., Vogelzang N. J., Bastos B. R., Weiss G. J., Fernandez C., Sutherland W., Sato H., Pierceall W. E., Weaver D., Slough S., Wasserman E., Kufe D. W., Von Hoff D., Kawabe T. & Sharma S. (20111007). Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Shapiro Geoffrey I, Tibes Raoul, Gordon Michael S, Wong Bryan Y, Eder Joseph Paul, Borad Mitesh J, Mendelson David S, Vogelzang Nicholas J, Bastos Bruno R, Weiss Glen J, Fernandez Cristian, Sutherland William, Sato Hitoshi, Pierceall William E, Weaver David, Slough Scott, Wasserman Ernesto, Kufe Donald W, Von Hoff Daniel, Kawabe Takumi and Sharma Sunil. 20111007. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Shapiro G. I., Tibes R., Gordon M. S., Wong B. Y., Eder J. P., Borad M. J., Mendelson D. S., Vogelzang N. J., Bastos B. R., Weiss G. J., Fernandez C., Sutherland W., Sato H., Pierceall W. E., Weaver D., Slough S., Wasserman E., Kufe D. W., Von Hoff D., Kawabe T. and Sharma S. (20111007). Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Shapiro Geoffrey I, Tibes Raoul, Gordon Michael S, Wong Bryan Y, Eder Joseph Paul, Borad Mitesh J, Mendelson David S, Vogelzang Nicholas J, Bastos Bruno R, Weiss Glen J, Fernandez Cristian, Sutherland William, Sato Hitoshi, Pierceall William E, Weaver David, Slough Scott, Wasserman Ernesto, Kufe Donald W, Von Hoff Daniel, Kawabe Takumi and Sharma Sunil. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20111007.